Enzo Biochem (ENZ, $3.75) posts +62% year-over-year revenue growth
Enzo Biochem posted a strong increase in revenue for its fiscal 2021 second quarter, ended Jan. 31, amid strong demand for the life sciences’ company’s testing equipment amid COVID-19 pandemic.
Revenue climbed +62% year-over-year to $31.5 million in the quarter. The company’s earnings came in at 5 cents a share, compared to a year-ago loss of - 16 cents a share.
“Our open system approach allows for the highest levels of flexibility and adaptability in the post COVID-19 environment,” Barry Weiner, Enzo’s president, said. "Our GENFLEX platform enables laboratories to use third-party or their own reagents on this open platform with ease and flexibility."
The company announced that founder Elazar Rabbani is stepping down as CEO. However, Rabbani would a director.
ENZ's Indicator enters downward trend
The Aroon Indicator for ENZ entered a downward trend on May 16, 2022. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 283 similar instances where the Aroon Indicator formed such a pattern. In 245 of the 283 cases the stock moved lower. This puts the odds of a downward move at 87%.
Current price $2.39 crossed the support line at $3.31 and is trading between $3.31 support and $-3.34 resistance lines. Throughout the month of 04/13/22 - 05/16/22, the price experienced a -18% Downtrend. During the week of 05/09/22 - 05/16/22, the stock fell -0.42%.
The Momentum Indicator moved below the 0 level on April 08, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ENZ as a result. In 84 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ENZ turned negative on April 25, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENZ's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 70 cases where ENZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +4.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENZ advanced for three days, in 178 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 54%. During the last month, the daily ratio of advancing to declining volumes was 1 to 2.48.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.757) is normal, around the industry mean (7.459). P/E Ratio (232.558) is within average values for comparable stocks, (92.284). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.305). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.966) is also within normal values, averaging (95.433).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
The average market capitalization across the Medical Specialties Industry is 5.8B. The market cap for tickers in the group ranges from 775 to 3.9T. MKYSF holds the highest valuation in this group at 3.9T. The lowest valued company is BIIO at 775.
The average weekly price growth across all stocks in the Medical Specialties Industry was 0.4%. For the same Industry, the average monthly price growth was -14.3%, and the average quarterly price growth was -31.79%. PMSNF experienced the highest price growth at 53%, while TNON experienced the biggest fall at -83.59%.
The average weekly volume growth across all stocks in the Medical Specialties Industry was -13.53%. For the same stocks of the Industry, the average monthly volume growth was -19.1% and the average quarterly volume growth was -10.39%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the Volume Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 36%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.02.
10 stocks in the group of tickers confirmed the positive outlook based on the RSI indicator with average odds of 86%.
The most notable companies in this group are Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Cel-Sci Corp (ASE:CVM).
The average market capitalization across the group is 763M. The market cap for tickers in the group ranges from 18.6M to 4.1B. NVAX holds the highest valuation in this group at 4.1B. The lowest valued company is IDRA at 18.6M.
The average weekly price growth across all stocks in the group was -2.39%. For the same group, the average monthly price growth was -25.14%, and the average quarterly price growth was -56.51%. SGMO experienced the highest price growth at 4.86%, while IDRA experienced the biggest fall at -13.8%.
- 5/14/22 4:23 AM: Idera Pharmaceuticals (IDRA, $0.35) is a top weekly loser for penny stocks, falling -16.58%
- 5/12/22 5:38 AM: Pluristem Therapeutics (PSTI, $1.43) is a top weekly loser for penny stocks, falling -15.88%
- 5/10/22 5:36 AM: Genetic Technologies (GENE, $1.32) is a top weekly loser for penny stocks, falling -16.82%
The average weekly volume growth across all stocks in the group was -56.14%. For the same stocks of the group, the average monthly volume growth was -35.11% and the average quarterly volume growth was -41.37%
- 5/14/22 4:16 AM: The volume for Compugen stock increased for four consecutive days, resulting in a record-breaking daily growth of 84% of the 65-Day Volume Moving Average
- 4/20/22 8:52 AM: The volume for Idera Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 349% of the 65-Day Volume Moving Average
- 3/19/22 4:43 AM: The volume for Agenus stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows